Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Shares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

RedHill Biopharma (RDHL) Income from Continuing Operations: 2009-2024

Historic Income from Continuing Operations for RedHill Biopharma (RDHL) over the last 16 years, with Dec 2024 value amounting to -$8.3 million.

  • RedHill Biopharma's Income from Continuing Operations rose 231.03% to $58.9 million in Q2 2023 from the same period last year, while for Jun 2023 it was -$40.0 million, marking a year-over-year increase of 75.62%. This contributed to the annual value of -$8.3 million for FY2024, which is 134.57% down from last year.
  • RedHill Biopharma's Income from Continuing Operations amounted to -$8.3 million in FY2024, which was down 134.57% from $23.9 million recorded in FY2023.
  • RedHill Biopharma's 5-year Income from Continuing Operations high stood at $51.2 million for FY2020, and its period low was -$97.7 million during FY2021.
  • For the 3-year period, RedHill Biopharma's Income from Continuing Operations averaged around -$18.7 million, with its median value being -$8.3 million (2024).
  • In the last 5 years, RedHill Biopharma's Income from Continuing Operations tumbled by 290.92% in 2021 and then spiked by 133.37% in 2023.
  • Over the past 5 years, RedHill Biopharma's Income from Continuing Operations (Yearly) stood at $51.2 million in 2020, then crashed by 290.92% to -$97.7 million in 2021, then increased by 26.68% to -$71.7 million in 2022, then skyrocketed by 133.37% to $23.9 million in 2023, then plummeted by 134.57% to -$8.3 million in 2024.